- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02102906
TMS and Attentional Bias in Functional Motor Disorder
Functional motor disorders, also called motor conversion disorder, are common reasons for attendance at neurology outpatient clinics. Patients with functional motor disorders are more common than patients with multiple sclerosis and have similar levels of disability but more psychological morbidity.
There is limited evidence for effective treatments in functional motor disorders. A small number of studies of transcranial magnetic stimulation (TMS), a painless method of cortical stimulation, have reported improvement in functional weakness after this treatment including in patients with symptoms of several years duration. The Investigators intend to trial TMS in a group of 40 patients with functional motor disorder, randomising patients to immediate or delayed treatment and therefore comparing a single session of TMS with routine clinical care. The Investigators will also ask patients to undergo tests of attentional focus in a cognitive neuroscience laboratory - these experiments will be analysed separately from TMS trial data.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A randomised non-blinded controlled study design will be used, with 3 months of treatment as usual as the control condition and a single session of TMS as the treatment condition.
40 patients with functional unilateral upper limb weakness will be recruited from neurology and neuropsychiatry clinics in Edinburgh and randomised to either immediate treatment or to 3 month delay during which they will receive routine clinical care. Randomisation will be performed using computerised random number generator by a person not involved with the study.
Patients randomised to delay will complete baseline measures of disability and motor function including SF36, modified Rankin score and study specific questionnaires, and will repeat these after 3 months. Patients undergoing immediate treatment will complete the same questionnaires immediately before and 3 months after treatment. All individuals receiving TMS treatment will undergo tests of grip strength and tapping frequency immediately before and after treatment.
The treatment and experiments involved will be as follows. Patients will attend the PPLS Cognitive Neuroscience Laboratory at George Square, University of Edinburgh for a single 2 hour session. During the first hour they will complete baseline symptom severity and disability questionnaires and will undertake a series of 3 experiments. Experiments involve participants sitting with their head on a chin-rest looking at either a computer screen or at lights projected onto their own hands, and for one experiment with a vibrating 'buzzer' taped to each hand. They will be asked to respond verbally in experiments which test their response to distracting attentional 'cues' either visual or vibrotactile. These experiments will take less than 1 hour. In anaylsis, performance will be compared between affected and unaffected sides (ie left hand and right hand), and will also be compared with performance of a group of 15 healthy control participants recruited from spouses or partners.
Patient participants will then receive treatment with 20 single pulses of TMS to the motor cortex at 120% motor threshold. These will cause visible and palpable 'jerks' of the affected limb. Between stimulations the researcher will offer verbal encouragement and ask the participant to move the affected limb if possible. Treatment will take less than 1 hour.
The primary outcome measures are patient-rated symptom severity and disability and simple statistical analysis will be used to compare outcome after 3 months of treatment as normal and 3 months after a single session of TMS treatment. Secondary outcome measures include grip strength and tapping frequency before and after treatment. Data will be analysed on an intention-to-treat basis. Data from attentional tests will be analysed separately.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH4 2XU
- Department of Clinical Neurosciences, Western General Hospital
-
Edinburgh, Scotland, United Kingdom, EH8 9AD
- Department of Psychology, University of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical diagnosis, by a consultant neurologist, of functional motor disorder
- functional unilateral upper limb weakness present for 50% or more of the time
- age 18-75
- ability to give informed consent
Exclusion Criteria:
- difficulties in understanding spoken or written English
- history of epileptic seizures (non-epileptic seizures will not be an exclusion criteria)
- alcohol dependence
- severe co-morbid physical or psychiatric disorder
- factitious disorder
- patients unable to receive TMS because of metal implants such as pacemakers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TMS treatment
Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout.
Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
|
Single pulse TMS - 20 pulses at 120% motor threshold.
Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-rated disability
Time Frame: An average of 3 months after day of attendance for TMS treatment.
|
SF36 score and Modified Rankin Score
|
An average of 3 months after day of attendance for TMS treatment.
|
Patient rated symptom severity
Time Frame: An average of 3 months after day of attendance for TMS treatment
|
Assessed using a Likert scale.
|
An average of 3 months after day of attendance for TMS treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Grip strength
Time Frame: Between 10 minutes and one hour before TMS treatment, and between 10 minutes and 1 hour after TMS treatment.
|
Between 10 minutes and one hour before TMS treatment, and between 10 minutes and 1 hour after TMS treatment.
|
Hand tapping frequency
Time Frame: Between 10 minutes and one hour before TMS treatment, and between 10 minutes and 1 hour after TMS treatment
|
Between 10 minutes and one hour before TMS treatment, and between 10 minutes and 1 hour after TMS treatment
|
Patient rated treatment discomfort
Time Frame: Between 10 minutes and 1 hour after TMS treatment.
|
Between 10 minutes and 1 hour after TMS treatment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attentional focus / distractibility
Time Frame: Tests performed during the 1-2 hours before treatment.
|
A short series of neurocognitive experiments based on a modified Posner test will examine for differences in attentional focus between affected and unaffected limbs and will also compare performance with a group of healthy controls recruited from spouses.
|
Tests performed during the 1-2 hours before treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jon Stone, MBChB PhD FRCP, NHS Lothian
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conversion Disorder
-
University Hospital, Clermont-FerrandRecruitingConversion Disorder in ChildrenFrance
-
Swiss Paraplegic Research, NottwilCompletedParalysis | Functional Neurological Symptom Disorder | Conversion Disorder With Weakness/ParalysisSwitzerland
-
King's College LondonKing's College Hospital NHS Trust; South London and Maudsley NHS Foundation...RecruitingFunctional Neurological Symptom DisorderUnited Kingdom
-
University Hospital, GrenobleCompletedFunctional Neurological Symptom DisorderFrance
-
Centre Psychothérapique de NancyNot yet recruitingDissociative DisorderFrance
-
University College, LondonNational Institute for Health Research, United KingdomCompleted
-
Mahidol UniversityCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Oslo University HospitalNorwegian School of Sport SciencesUnknown
-
University of FribourgInsel Gruppe AG, University Hospital BernRecruitingFunctional Neurological DisorderSwitzerland
Clinical Trials on Transcranial magnetic stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
George Mason UniversityMedStar National Rehabilitation NetworkCompletedStroke | Stroke, Ischemic | Hemiparesis | Cerebral Vascular AccidentUnited States
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Russian Academy of Medical SciencesCompletedStrokeRussian Federation
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingMajor Depressive DisorderCanada
-
University Hospital TuebingenFederal Ministry of Health, Germany; University of Ulm; Department of Psychiatry... and other collaboratorsRecruitingMajor Depressive DisorderGermany
-
VA Office of Research and DevelopmentRecruitingDepression | Gulf War IllnessUnited States
-
National Institute of Mental Health (NIMH)CompletedHealthy VolunteersUnited States
-
University of ManitobaManitoba Medical Service FoundationSuspendedObsessive Compulsive DisorderCanada
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed